Cargando…

Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study

Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armentaro, Giuseppe, D’Arrigo, Graziella, Magurno, Marcello, Toscani, Alfredo F., Condoleo, Valentino, Miceli, Sofia, Cassano, Velia, Maio, Raffaele, Arturi, Franco, Tripepi, Giovanni, Sesti, Giorgio, Sciacqua, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415264/ https://www.ncbi.nlm.nih.gov/pubmed/34483943 http://dx.doi.org/10.3389/fphar.2021.733475

Ejemplares similares

Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study
por: Armentaro, Giuseppe, et al.
Publicado: (2022)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
por: Cassano, Velia, et al.
Publicado: (2022)

Association Between Sleep Apnea and Valvular Heart Diseases
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction
por: Cloro, Cosima, et al.
Publicado: (2022)

Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance
por: Cassano, Velia, et al.
Publicado: (2020)

Ferritin modifies the relationship between inflammation and arterial stiffness in hypertensive patients with different glucose tolerance
por: Sciacqua, Angela, et al.
Publicado: (2020)

Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
por: Armentaro, Giuseppe, et al.
Publicado: (2023)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients
por: Armentaro, Giuseppe, et al.
Publicado: (2022)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery”
por: Romano, Giuseppe, et al.
Publicado: (2019)

Alkaline phosphatase affects renal function in never-treated hypertensive patients: effect modification by age
por: Sciacqua, Angela, et al.
Publicado: (2020)

Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study
por: Pelaia, Corrado, et al.
Publicado: (2021)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension
por: Pelaia, Corrado, et al.
Publicado: (2023)

Decreased Pulse Wave Velocity in a Systemic Sclerosis Population: Preliminary Results from a Cross-Sectional Study
por: Iaquinta, Francesco Salvatore, et al.
Publicado: (2022)

Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
por: Mazzetti, Simone, et al.
Publicado: (2020)

New potential biomarkers for early chronic kidney disease diagnosis in patients with different glucose tolerance status
por: Cassano, Velia, et al.
Publicado: (2023)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences
por: Castrichini, Matteo, et al.
Publicado: (2020)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
por: De Vecchis, Renato, et al.
Publicado: (2020)

Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes
por: Ministrini, Stefano, et al.
Publicado: (2021)

Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
por: Saengklub, Nakkawee, et al.
Publicado: (2021)

Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan
por: Dini, Frank L., et al.
Publicado: (2022)

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry
por: Mandoli, Giulia Elena, et al.
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
por: Vitale, Giuseppe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eqfgrecjqt4uvpl7akd073jv6b